Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1PRETEXT I Hepatoblastoma 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Castleman Disease 1

Interventions

Specimen Handling 51Carboplatin 49pembrolizumab 45Magnetic Resonance Spectroscopy 43Pemetrexed 39Cisplatin 34Paclitaxel 24durvalumab 23osimertinib 20Nivolumab 19Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 14Taxes 12Radiotherapy 12Immunoglobulin G 12Disulfides 12130-nm albumin-bound paclitaxel 12Etoposide 11Educational Status 11Biopsy 11Radiation 10Drug Therapy 10Blood Specimen Collection 10Platinum 9Early Intervention, Educational 9Cetuximab 9Methods 8Bevacizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × temsirolimus × 90 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡